ライフサイエンスコーパス: portal vein thrombosis

1 ut was present in 62.5% of the patients with portal vein thrombosis.

2 There was no incidence of hepatic artery or portal vein thrombosis.

3 Three (2.9%) grafts were lost due to portal vein thrombosis.

4 y independent risk factor for pre-transplant portal vein thrombosis.

5 es because of unexpected acute rejection and portal vein thrombosis.

6 ing for age, sex, treatment, tumor size, and portal vein thrombosis.

7 patient required retransplantation, owing to portal vein thrombosis.

8 ies, 8 required surgical shunts for complete portal vein thrombosis.

9 hic scan showed superior mesenteric vein and portal vein thrombosis.

10 t entry criteria, and 2 were excluded due to portal vein thrombosis.

11 4), acute chest syndrome (5), pneumonia (2), portal vein thrombosis (1), priapism (1), hemolytic urem

12 were mainly rejected for comorbidity (19%), portal vein thrombosis (16%), previous surgery (9%), obe

13 ently in OPV than in cirrhosis: extrahepatic portal vein thrombosis (18 [43%] of 42 vs five [12%] of

14 .4%; 20-year survival, 12.5%). patients with portal vein thrombosis and biliary cirrhosis demonstrate

15 wo (16.3%) patients developed pre-transplant portal vein thrombosis and its presence had no impact in

16 tic thrombosis, and radiologic management of portal vein thrombosis and stenosis has decreased operat

17 Two donors developed portal vein thrombosis, and 1 had inferior vena caval th

18 C, 56% had more than 1 tumor nodule, 24% had portal vein thrombosis, and 29% did not receive any canc

19 ism, disseminated intravascular coagulation, portal vein thrombosis, and arterial thromboembolism.

20 as hepatorenal syndrome, hepatichydrothorax, portal vein thrombosis, and Budd-Chiari syndrome.

21 analysis Child-Pugh score, presence of HCC, portal vein thrombosis, and lack of secondary prophylaxi

22 as associated with an increased incidence of portal-vein thrombosis, as compared with placebo.

23 Portal vein thrombosis at listing was not associated wit

24 Portal vein thrombosis at LT is associated with early (9

25 tis/cholecystitis, pancreatitis, hemorrhage, portal vein thrombosis, bowel wall perforation, or dehyd

26 f orthotopic liver transplantation, in which portal vein thrombosis developed in the immediate postop

27 operation (MLPVB) in correcting extrahepatic portal vein thrombosis (EHPVT) in children.

28 s of the liver in children with extrahepatic portal vein thrombosis (EHPVT), with surgical outcome af

29 Budd-Chiari syndrome (BCS) and portal vein thrombosis have been reported to be associat

30 last decade a large number of patients with portal vein thrombosis have undergone successful liver t

31 We aimed to characterize the pre-transplant portal vein thrombosis in a cohort of liver transplant r

32 ascular stent placement for the treatment of portal vein thrombosis in liver transplant recipients.

33 nt placement were successfully used to treat portal vein thrombosis in patients with recent liver tra

34 Portal vein thrombosis is a frequent complication in end

35 Portal vein thrombosis is the most common cause of porta

36 patients with Budd-Chiari syndrome and with portal vein thrombosis, Kiladjian et al observed that JA

37 n associated with hepatic artery (n = 15) or portal vein thrombosis (n = 14).Mean surgical time was 1

38 pared with non-BCS liver recipients), one of portal vein thrombosis (nonsignificant [NS]), and one of

39 t survival for patients who have experienced portal vein thrombosis or stenosis is 61% and 67%, respe

40 There were no wound infections, portal vein thrombosis, or fluid and electrolyte abnorma

41 ardial infarct, perioperative hemorrhage, or portal vein thrombosis--or death occurred as a result of

42 001), MELD score greater than 10 (P = .001), portal vein thrombosis (P = .0001), and tumor diameter g

43 nt differences in hepatic artery thrombosis, portal vein thrombosis, primary nonfunction, and biliary

44 s possible even in the presence of recipient portal vein thrombosis, provided that hepatopetal portal

45 logy Group (ECOG), presence of cirrhosis and portal vein thrombosis (PVT) (none, branch, and main).

46 Portal vein thrombosis (PVT) and different cardiovascula

47 patients of liver cirrhosis associated with portal vein thrombosis (PVT) can be effectively treated

48 In cirrhosis, portal vein thrombosis (PVT) could be a cause or a conse

49 Portal vein thrombosis (PVT) has been reported to have a

50 low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced c

51 Portal vein thrombosis (PVT) is common in patients with

52 Nonneoplastic portal vein thrombosis (PVT) is frequent in patients wit

53 ate and survival of hepatocellular carcinoma portal vein thrombosis (PVT) patients treated with (90)Y

54 Patients with Child-Pugh B disease who had portal vein thrombosis (PVT) survived 5.6 months (95% co

55 ed-stage hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with (90)Y radioemb

56 onths with no significant difference between portal vein thrombosis (PVT) versus no PVT (7 versus 13

57 The 1-year probability of developing portal vein thrombosis (PVT) was 9%, and 53% of patients

58 tients with chronic noncirrhotic, nontumoral portal vein thrombosis (PVT), the usually recommended st

59 ocellular carcinoma (HCC), including 16 with portal vein thrombosis (PVT), were treated with (90)Y-lo

60 leeding from portal hypertension but also by portal vein thrombosis (PVT).

61 yndrome (BCS) and nonmalignant, noncirrhotic portal vein thrombosis (PVT).

62 Venous complications included portal vein thrombosis, transverse and sagittal sinus th

63 atocellular carcinoma (HCC) with and without portal vein thrombosis underwent radioembolization with

64 ease, cytomegalovirus infection and disease, portal vein thrombosis, UNOS status, Childs-Pugh score,

65 Portal vein thrombosis was identified in 17 of 21 patien

66 Portal vein thrombosis was independently associated with

67 Portal vein thrombosis was present in 11 patients (6%).

68 60.1 years; range, 32-75 years) with HCC and portal vein thrombosis who were examined with both contr